KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Other financing activities (2018 - 2025)

Rigel Pharmaceuticals (RIGL) has 8 years of Other financing activities data on record, last reported at $4.3 million in Q3 2025.

  • For Q3 2025, Other financing activities rose 2603.16% year-over-year to $4.3 million; the TTM value through Sep 2025 reached $6.6 million, up 573.91%, while the annual FY2024 figure was $2.0 million, 87.23% up from the prior year.
  • Other financing activities reached $4.3 million in Q3 2025 per RIGL's latest filing, up from $418000.0 in the prior quarter.
  • Across five years, Other financing activities topped out at $4.3 million in Q3 2025 and bottomed at $1000.0 in Q1 2023.
  • Average Other financing activities over 5 years is $852941.2, with a median of $486000.0 recorded in 2023.
  • Peak YoY movement for Other financing activities: crashed 99.89% in 2023, then skyrocketed 8800.0% in 2024.
  • A 5-year view of Other financing activities shows it stood at $1.1 million in 2021, then plummeted by 44.79% to $599000.0 in 2022, then fell by 18.86% to $486000.0 in 2023, then surged by 201.44% to $1.5 million in 2024, then surged by 191.54% to $4.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Other financing activities were $4.3 million in Q3 2025, $418000.0 in Q2 2025, and $484000.0 in Q1 2025.